In recent years, there has been an increasing interest in non-hematopoietic pluripotent progenitor cells that are found in the bone marrow. Mesenchymal stem cells (MSCs) are the first non-hematopoietic progenitors to be isolated from the bone marrow and extensively characterized. In addition to their ability to support hematopoiesis, MSCs can differentiate into osteocytes, chondrocytes, tenocytes, adipocytes and smooth muscle cells. This article will review our current understanding of bone marrow stroma and MSCs and their potential therapeutic role in the setting of hematopoietic stem cell transplantation. Bone Marrow Transplantation (2001) 27, 235-239.
What are mesenchymal stem cells?
Friedenstein initially reported in 1976 that clonogenic stromal cells could be derived from bone marrow. 1 Several groups subsequently described non-hematopoietic, plasticadherent progenitor cells derived from human bone marrow aspirates, which were capable of differentiating into mature mesenchymal cells. [2] [3] [4] [5] [6] It is thought that mesenchymal progenitors give rise to adventitial and other mesenchymal cells in the marrow and constitute the microenvironment for hematopoiesis; such cells fabricate the connective tissue scaffolding and produce cytokines, chemokines and extracellular matrix proteins that regulate hematopoietic homing and proliferation. 7, 8 These progenitors also can differentiate into myocytes, 9 not part of the bone marrow microenvironment. Furthermore, recent characterization of hepatocyte 10 and glial [11] [12] [13] differentiation potential of marrow stem cells raises the possibility that bone marrow may harbor pluripotential stem cells, perhaps as embryonic remnants. Investigators at Case Western Reserve University described a uniform population of adherent cells with extensive proliferative capacity and the ability to differentiate along the osteogenic, chondrogenic and adipogenic lineages both in vitro and in vivo. These cells were named mesenchymal stem cells (MSCs).
14 MSCs are likely to represent a restricted progeny of putative pluripotent stem cells selected on the basis of their rapid plastic adherence and high proliferation potential in 10% fetal calf serum. In unstimulated cultures, MSCs appear as fusiform fibroblasts with expression of unique surface proteins (SH2 and SH3) 15 not found on hematopoietic precursors. MSCs lack expression of hematopoietic markers such as CD45, CD14, CD11 and CD34 and constitutively secrete IL-6, -7, -8, -11, -12, -14, -15, M-CSF, LIF, Flt-3 ligand, and SCF and are inducible with IL-1␣ to produce IL-1␣, LIF, G-CSF and GM-CSF. 8, 16, 17 Similar to Dexter-type stromal cultures, MSCs can support human long-term culture-initiating cells (LTC-ICs). 17 The pivotal role of MSCs in the bone marrow microenvironment and their ability to support hematopoiesis first sparked Bone Marrow Transplant physicians' interest in these cells. A number of studies have shown that chemotherapy and radiation damage the marrow microenvironment and diminish its hematopoietic support function. [18] [19] [20] Therefore it seemed logical that if transplanted, MSCs could restore the marrow microenvironment and support autologous and allogeneic hematopoietic engraftment and regeneration.
Can conventional bone marrow transplantation repopulate the stromal cells in bone marrow microenvironment?
Independent laboratories have shown that recipients of unmanipulated allogeneic bone marrow transplantation contain only host-type marrow stromal cells and MSCs in their bone marrow. 21, 22 These results are attributed to the inability of the conditioning regimen to ablate host marrow stroma and/or the inability of stromal progenitors to engraft. In addition, the number of MSCs is estimated to be too few in an average bone marrow graft (2-5 MSCs per 1 ϫ 10 6 mononuclear cells, suggesting that a bone marrow graft comprised of 2 ϫ 10 8 MNC/kg would contain 400-1000 MSCs/kg). On the other hand, a recent report noted that allogeneic osteoblasts could be detected in recipients with osteogenesis imperfecta (OI) after sibling-matched allogeneic bone marrow transplantation. 23 It is not clear if this observation indicates if osteoblasts were passively transferred to the recipient, or whether MSCs present in the marrow graft were capable of homing to the bone and differentiating into osteoblasts. Nevertheless, these data suggest that osteoblasts may be transplanted successfully in certain conditions and diseases, although the optimal approach has not yet been established. Most of the patients undergoing allogeneic hematopoietic stem cell transplantation have hematologic malignancies and exhibit a relatively slow turnover of their mesenchymal tissues even after preparative therapy. In contrast, OI patients may have much faster turnover of their osteoid tissue. As a result, it may be possible to detect donor-derived osteoblasts, MSCs or both cells participating in this process, especially since normal osteoblasts have a competitive survival advantage compared to endogenous OI osteoblasts.
In the allogeneic transplantation field there is a trend towards using alternative grafts such as mobilized peripheral blood progenitor cells (PBPC) 24 and umbilical cord blood (UCB). We and others have been unable to detect or culture-expand MSCs from hematopoietic growth factor and/or chemotherapy-mobilized peripheral blood or from UCB. 25 Therefore bone marrow-derived MSCs may be even more important in patients receiving PBPCs or UCB. The question still remains whether the bone marrow microenvironment can be repopulated by allogeneic bone marrow or culture-expanded MSCs in patients who have no intrinsic mesenchymal defect. Furthermore, it remains to be shown if this cellular therapy improves engraftment rates, particularly if UCB grafts containing marginal numbers of stem cells are utilized.
Can culture-expanded mesenchymal stem cells be successfully transplanted?
In murine models, stromal chimerism has been achieved using infusions of culture-expanded stromal progenitors. Pereira et al 26 infused normal mouse stromal cells into irradiated transgenic mice that exhibit the osteogenesis imperfecta (OI) phenotype. Donor MSCs distributed to spleen, bone, lung and cartilage and were detected 2.5 months later. Remarkably, when these cells lodged into bones, they differentiated into osteocytes and produced normal collagen, which mineralized and partially corrected the OI phenotype. In the absence of a bone defect such as OI, it has been difficult to demonstrate functional engraftment of donor MSCs. Green fluorescent protein (GFP)-marked canine MSCs were infused into autologous as well as DLAidentical litter-mate dogs following 920 cGy total body radiation along with unmodified bone marrow or PBPCs. PCR evidence of GFP-marked canine MSCs was found predominantly in the marrow of sternum, ribs, and limbs at 6 and 14 weeks post infusion. 27 More recently, xenotransplantation models have been developed to determine the homing of human MSCs in animals. Human MSCs could be detected predominantly in the bone marrow and less frequently, in other organs of immunodeficient NOD-SCID mice 8 weeks after infusion. 28 However, the contribution of these human MSCs to mouse bone marrow activity is not well understood. Preliminary data indicate that MSC co-infusion enhances human hematopoiesis in NOD-SCID mice. 29 High in vitro proliferative potential of human MSCs 30 provided transplanters with an opportunity to expand MSC numbers from ෂ400/kg to 1-10 ϫ 10 6 /kg by ex vivo culture prior to transplantation. Theoretically, one can cultureexpand the numbers of MSCs that exist in the human body from a 10-20 ml bone marrow aspirate. In a pilot study, our group demonstrated the safety of ex vivo expansion and subsequent infusion of autologous MSCs in 15 patient volunteers. 31 These individuals had hematologic malignancies that were in remission at the time of MSC collection and infusion and were not given preparative chemotherapy. Only 1-50 ϫ 10 6 total autologous MSCs were intravenously infused without any toxicity. We then conducted a phase I-II clinical trial to determine the feasibility, safety and hematopoietic effects of bone marrow-derived, cultureexpanded autologous MSCs infused into breast cancer patients in the course of high-dose chemotherapy (STAMP V) and hematopoietic stem cell rescue. 32 Relatively small volumes of marrow (25 ml) were collected in an ambulatory setting from the posterior superior iliac crests and MSCs were culture-expanded ex vivo from these samples. Autologous MSCs were infused i.v. at a dose of 1.0 to 2.2 ϫ 10 6 per kg patient weight without any toxicity. In 13 of 21 patients, clonogenic MSCs could be identified in the circulation within 60 min of infusion, indicating survival and brief persistence in the circulation. Hematopoietic recovery was rapid (neutrophils Ͼ500 l in 8 days and platelets Ͼ20 000/l in 8.5 days, median). Since patients were also supported with large numbers of autologous peripheral blood CD34
+ cells, the role of MSCs in enhancing hematopoietic recovery could not be ascertained. A recent randomized trial was undertaken to determine the contribution of autologous MSCs to the tempo of hematopoietic recovery after PBPC infusion. Patients were given either culture-expanded MSCs i.v. (2 ϫ 10 6 /kg) or no MSC infusion after 'STAMP I' chemotherapy. Preliminary data indicate that MSCs hasten hematologic recovery (Baynes and Peters, personal communication).
A number of patients fail to mobilize sufficient CD34 + cells and this otherwise acceptable patient group may be excluded from autotransplants. While some investigators utilize a supplemental bone marrow harvest in addition to the limited PBPC, transplant-related mortality often remains high in these patients. Trials using autologous MSCs in patients with a sub-optimal PBPC collection may prove beneficial. One question is whether these 'poor mobilizing' patients will also have poor MSC yields due to prior chemotherapy and stromal injury. The immunologic inertness of MSCs may allow use of normal donor allogeneic MSCs in the context of autologous PBPC transplantation (see below). Such a trial in patients with lymphoma who have sub-optimal PBPC harvest is about to start at the Ireland Cancer Center (UHC/CWRU). Autologous PBPCs will be supplemented by allogeneic MSCs obtained from haploidentical sibling, parent or child.
What are the immunologic consequences of allogeneic MSC transplantation?
Laboratory experiments designed to expand hematopoietic stem cells ex vivo using support from adherent MSCs indicated that unrelated donor MSCs do not generate alloreactive lymphocytes in culture. These findings were corroborated in controlled experiments 33, 34 and in fact, revealed a remarkable ability of MSCs to down-regulate an allo-immune response. This finding led to the design of animal and clinical experiments in the context of allograft rejection and GVHD modulation. Using a baboon skin graft model, Bartholomew and co-workers 35 showed that infusion of ex vivo-expanded donor (baboon) MSCs at a dose of 20 ϫ 10 6 MSC/kg recipient weight prolonged time to rejection of histoincompatible skin grafts. Even 'thirdparty' baboon MSCs, obtained from neither recipient nor skin graft donor, appeared to suppress alloreactivity in vivo.
To determine whether co-infusion of allogeneic MSCs could improve engraftment rates and decrease GVHD in patients undergoing matched sibling stem cell transplantation, a multi-center phase I study has been initiated (see Table 1 ). In this trial, allogeneic MSC dose is escalated from 1 to 5 ϫ 10 6 /kg in cohorts of patients with hematological disorders receiving concomitant allogeneic bone marrow or PBPC transplantation. Preliminary data suggest a positive effect of MSC transplantation compared to historical controls. Ultimately, this strategy must be tested in phase III trials of HLA-identical sibling transplants and phase II trials of matched unrelated donor allogeneic stem cell (peripheral blood, bone marrow and umbilical cord blood) transplantation supplemented with third-party MSCs. 
Bone Marrow Transplantation
Normal human MSCs were shown to express a number of lysosomal enzymes that can potentially correct storage disorders in mesenchymal tissues. Thus, allogeneic normal donor MSC transplantation is also being tested in patients with inborn metabolic disorders to halt their disease progression. 36 In this trial, patients who previously underwent allogeneic bone marrow transplantation from their HLAidentical sibling receive 2-10 ϫ 10 6 allogeneic donor MSCs/kg. Preliminary results indicate that allogeneic MSCs are well tolerated and there is some evidence of clinical benefit. Assessment of donor MSC chimerism in the recipient is currently underway. As expected there was no immune (T cell) response against infused MSCs in these patients who are already fully engrafted with donor hematopoietic and immune cells.
Future applications
In contrast to poorly characterized bone marrow 'stroma' cultures, MSCs can be generated as a homogenous population of cells that can be quantified, qualitatively analyzed and ex vivo manipulated. Therefore MSCs represent excellent cellular vehicles to express and deliver therapeutic genes or as support cells in hematopoietic stem cell expansion systems. During the ex vivo culture period, MSCs can be transduced efficiently with retroviral vectors to express genes of interest. Human MSCs were transduced by a retroviral vector containing the lacZ gene. 37 LacZ-transduced human MSCs were shown to differentiate into osteoblasts in ceramic cubes implanted into SCID mice. Six to 9 weeks after implantation, transduced human MSCs formed bone in these cubes and stained blue with X-gal indicating ␤-galactosidase expression. These data indicate that retrovirally transduced MSCs retain their potential to differentiate into osteoblasts in vivo. Canine and murine MSCs were transduced with hormone or cytokine genes such as human growth hormone or human interleukin-3 and infused into experimental animals. [38] [39] [40] [41] Protein products were detected in the plasma for a number of months. Further development of these strategies which will allow sustained and regulated gene expression from transduced MSCs in vivo is ongoing.
UCB represents a potentially attractive alternative source of hematopoietic stem cells for patients who require allogeneic stem cell transplantation. UCB is advantageous compared to other alternative donor sources since the graft is rapidly available, and the potential for GVHD in recipients may be reduced despite HLA disparity. In adults, however, this approach has been hampered by the small numbers of hematopoietic stem cells available in a single UCB unit. In particular, the time to neutrophil engraftment has been relatively long. Several groups are now exploring ex vivo expansion of cord blood cells in both adults and children using the combination of early acting cytokines and an adherent MSCs, either autologous or from a third party (eg parent or sibling). It will be intriguing to see the effects of such expansion systems, not only on the rate and pace of engraftment but also on the incidence and severity of GVHD.
Clinical applications of human MSCs are evolving rapidly with ambitious goals of improving hematopoietic engraftment rate and pace, ameliorating or preventing GVHD, correcting inborn metabolic errors and delivering a variety of therapeutic genes. A number of challenging fundamental questions regarding the biology and therapeutic potential of MSCs are still unanswered. The search continues for a sub-population of MSCs with in vivo selfrenewal and engraftment potential. Size and surface characteristics of these cells are re-examined to understand barriers to their homing in vivo. In the clinical setting, it remains to be seen whether transplantation of MSCs has significant value and if pre-culture of hematopoietic stem cells with MSCs prior to transplantation changes their engraftment, immunologic properties, or both. These questions and others are likely to keep both basic scientists and clinical researchers busy during the next decade.
